ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

retatrutide

Also written as “Retatrutide”, “LY3437943” and “Retatrutide (LY3437943)”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Atherosclerosis · Non-alcoholic Fatty Liver Disease · Diabetes Mellitus, led by 2 companies.

Drug pageRetatrutide: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 22, 202333 company-led studies, 11 open or runningNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly3210 open or runningphase 3since May 22, 2023Feb 13, 2019Nov 2026phase 3 · NCT06662383
Hudson Biotechits history only11 open or runningphase 2since Mar 8, 2026Mar 8, 2026Mar 14, 2027phase 2 · NCT07467447
  • Named in Eli Lilly’s own pipeline as Retatrutide, phase 3, as of Oct 29, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 16 earlier studies, Feb 13, 2019 to Jul 17, 2023.

  1. Jan 19, 2023Named retatrutideINNProposed as its International Nonproprietary Name in WHO's List 128 · before, LY3437943
  2. Aug 16, 2023Phase 1 study in HealthyNCT06003465 · 57 enrolled · United States
  3. Sep 11, 2023Phase 1 study in OverweightNCT06039826 · 46 enrolled · United States
  4. Feb 8, 2024Phase 3 study in Diabetes Mellitus, Type 2NCT06260722 · 1,250 enrolled · United States, Argentina, Canada and more
  5. Mar 1, 2024Phase 3 study in Diabetes Mellitus, Type 2NCT06297603 · 341 enrolled · United States, Argentina, Brazil and more
  6. Mar 11, 2024Phase 1 study in ObesityNCT06313528 · 85 enrolled · United States
  7. Apr 3, 20242 phase 3 studiesNCT06354660, NCT06383390
  8. Oct 25, 2024Phase 3 study in ObesityNCT06662383 · 800 enrolled · United States, Argentina, Germany and more
  9. Jan 31, 2025Phase 1 study in HealthyNCT06808802 · 30 enrolled · Singapore
  10. Feb 28, 2025Phase 3 study in ObesityNCT06859268 · 643 enrolled · United States, Canada, United Kingdom
  11. May 14, 20252 phase 1 studiesNCT06982859, NCT06982846
  12. May 28, 2025Phase 3 study in ObesityNCT07035093 · 586 enrolled · United States, Argentina, Canada and more
  13. Aug 28, 2025Phase 3 study in Non-alcoholic Fatty Liver DiseaseNCT07165028 · 4,500 planned · United States, Argentina, Australia and more
  14. Nov 14, 2025Phase 3 study in ObesityNCT07232719 · 250 enrolled · United States, United Kingdom
  15. Jan 16, 2026Phase 3 study in ObesityNCT07357415 · 600 enrolled · United States, Argentina, Canada

Ahead

  1. Nov 2026Primary completion: phase 3 study in ObesityNCT06662383
  2. Jan 2027Primary completion: phase 1 study in Diabetes MellitusNCT06982859
  3. Jun 2027Primary completion: phase 3 study in ObesityNCT07232719
  4. Sep 2027Primary completion: phase 3 study in ObesityNCT07035093

TargetBeta

“Glucagon receptor agonist; Glucagon-like peptide 1 receptor agonist; Gastric inhibitory polypeptide receptor agonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
UBT251The United Laboratories Internationalphase 312
HRS-4729Jiangsu HengRui Medicinephase 25

Studies

All 32 Eli Lilly leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07357415Obesity · United States, Argentina, Canada3Active, not recruitingOct 2028600
NCT07232719Obesity · United States, United Kingdom3Active, not recruitingJun 2027250
NCT07165028Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more3RecruitingAug 20304,500
NCT07035093Obesity · United States, Argentina, Canada and more3Active, not recruitingSep 2027586
NCT06982859Diabetes Mellitus · Germany1Active, not recruitingJan 202795
NCT06982846Diabetes Mellitus, Type 2 · Austria1CompletedMay 4, 202680
NCT06859268Obesity · United States, Canada, United Kingdom3Active, not recruitingApr 2028643
NCT06808802Healthy · Singapore1CompletedApr 15, 202530
NCT06662383Obesity · United States, Argentina, Germany and more3Active, not recruitingNov 2026800
NCT06383390Atherosclerosis · United States, Argentina, Australia and more3Active, not recruitingFeb 202910,000
NCT06354660Diabetes Mellitus, Type 2 · United States, India, Mexico and more3CompletedJan 22, 2026537
NCT06313528Obesity · United States1CompletedAug 26, 202585
NCT06297603Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more3Active, not recruitingOct 26, 2026341
NCT06260722Diabetes Mellitus, Type 2 · United States, Argentina, Canada and more3Active, not recruitingAug 27, 20261,250
NCT06039826Overweight · United States1CompletedJul 11, 202446
NCT06003465Healthy · United States1CompletedFeb 8, 202457
NCT05959096Healthy · United States1CompletedJul 25, 202485
NCT05936151Overweight · United States, Canada, Italy and more2CompletedOct 1, 2025146
NCT05931367Obesity · United States, Australia, Canada and more3CompletedNov 14, 2025445
NCT05929079Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more3CompletedJun 16, 20261,152
NCT05929066Obesity · United States, Australia, Brazil and more3CompletedApr 6, 20262,335
NCT05916560Hepatic Insufficiency · United States1CompletedMar 2, 202543
NCT05882045Obesity · United States, Argentina, Australia and more3CompletedApr 16, 20261,946
NCT05757531Healthy · United States1CompletedJun 23, 20237
NCT05611957Renal Insufficiency · United States1CompletedSep 5, 202329
NCT05548231Overweight · China1CompletedJul 27, 202332
NCT05445232Obesity · United States1CompletedFeb 24, 202332
NCT04881760Obesity · United States, Puerto Rico2CompletedMay 16, 2022338
NCT04867785Diabetes Mellitus, Type 2 · United States, Puerto Rico2CompletedJul 8, 2022281
NCT04823208Diabetes Mellitus, Type 2 · Japan1CompletedJun 23, 202264
NCT04143802Diabetes Mellitus, Type 2 · United States1CompletedDec 28, 202072
NCT03841630Healthy · Singapore1CompletedJul 25, 201945

How it is read

Names in the registry

  • “Retatrutide”, 18 entries
  • “LY3437943”, 14 entries
  • “Retatrutide (LY3437943)”, 1 entry
  • “[¹⁴C]-LY3437943”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.